GSK plc
Search results
We are Haleon. We are a world-leading consumer health company with a clear purpose to deliver better everyday health with humanity. Our leading brands are built on science, innovation and human understanding and are trusted by millions of consumers globally.
Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers and Centrum vitamins.
Our leading brands are built on science, innovation and human understanding and are trusted by millions of consumers globally. Haleon has a strong portfolio of brands and is well positioned to play a vital role for people all around the world, in a sector that is growing and more relevant than ever.
Grow your career. Global brands, science, and human insight unite. Shape inclusive, sustainable health for millions. Dare to build a proud career. Join us in making a difference.
Haleon, formerly GSK Consumer Healthcare, is a company with a rich legacy and a deep passion for everyday health. We continue to raise the bar in product excellence across our key categories: Oral Health; Vitamins, Minerals and Supplements; Pain Relief; Respiratory Health; and Digestive Health.
The programme outlined the strategy for Haleon to deliver sustainable, above-market growth and strong value creation. Scroll down access the presentations, transcripts, press release and other supplementary information.
Welcome to Haleon HealthPartner. We’re here to support healthcare professionals. Join our community to access free personalised learning resources, explore the latest research, discover our products and get tools to help you provide the best care for your patients. Register now
Find the latest Haleon plc (HLN) stock quote, history, news and other vital information to help you with your stock trading and investing.
GSK plc (LSE/NYSE: GSK) today announced that, further to its announcement on 16 May 2024, GSK has agreed to sell 385,320,110 ordinary shares in Haleon plc (“Haleon”) at a price of 324 pence per share (the “Placing Shares”), raising gross proceeds of approximately £1,248m (the “Placing”).
Discover the science behind our innovations. We’re committed to building deep understanding of patients and science. To help you explore our portfolio, the Learning Lab will feature informative videos, clinical summaries and learning modules.
